Switch theme
Sign up to access all valuation multiples
Samchundang Pharm Co Ltd is engaged in manufacturing, distributing, importing, and exporting pharmaceuticals in South Korea. The company offers ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as gastro intestines and vitamins.
1943
n/a
Last FY Revenue $153M
Last FY EBITDA $14.9M
$2.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Samchundang Pharm achieved revenue of $153M and an EBITDA of $14.9M.
Samchundang Pharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Samchundang Pharm valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $153M | XXX | XXX | XXX |
| Gross Profit | XXX | $72.5M | XXX | XXX | XXX |
| Gross Margin | XXX | 47% | XXX | XXX | XXX |
| EBITDA | XXX | $14.9M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 10% | XXX | XXX | XXX |
| EBIT | XXX | $1.9M | XXX | XXX | XXX |
| EBIT Margin | XXX | 1% | XXX | XXX | XXX |
| Net Profit | XXX | -$7.9M | XXX | XXX | XXX |
| Net Margin | XXX | -5% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Samchundang Pharm's stock price is KRW 146500 (or $106).
Samchundang Pharm has current market cap of KRW 3.41T (or $2.5B), and EV of KRW 3.33T (or $2.4B).
See Samchundang Pharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4B | $2.5B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Samchundang Pharm has market cap of $2.5B and EV of $2.4B.
Samchundang Pharm's trades at 15.8x EV/Revenue multiple, and 162.8x EV/EBITDA.
Equity research analysts estimate Samchundang Pharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Samchundang Pharm's P/E ratio is not available.
See valuation multiples for Samchundang Pharm and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 15.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 162.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 1260.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -312.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -170.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSamchundang Pharm's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Samchundang Pharm's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Samchundang Pharm's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Samchundang Pharm and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Samchundang Pharm acquired XXX companies to date.
Last acquisition by Samchundang Pharm was XXXXXXXX, XXXXX XXXXX XXXXXX . Samchundang Pharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Samchundang Pharm founded? | Samchundang Pharm was founded in 1943. |
| Where is Samchundang Pharm headquartered? | Samchundang Pharm is headquartered in South Korea. |
| Who is the CEO of Samchundang Pharm? | Samchundang Pharm's CEO is Mr. In-seok Jeon. |
| Is Samchundang Pharm publicy listed? | Yes, Samchundang Pharm is a public company listed on KRX. |
| What is the stock symbol of Samchundang Pharm? | Samchundang Pharm trades under 000250 ticker. |
| When did Samchundang Pharm go public? | Samchundang Pharm went public in 2000. |
| Who are competitors of Samchundang Pharm? | Similar companies to Samchundang Pharm include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Samchundang Pharm? | Samchundang Pharm's current market cap is $2.5B |
| Is Samchundang Pharm profitable? | Yes, Samchundang Pharm is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
